Antagonizing TGF-beta activity with various ectodomains of TGF-beta receptors used in combination or as fusion proteins
First Claim
Patent Images
1. A transforming growth factor beta (TGF-beta or TGFβ
- ) antagonist composition comprising a therapeutically effective amount of one or more of;
(1) therapeutically active portions of soluble cell surface type II receptors (sRII);
(2) therapeutically active portions of soluble cell surface type III receptors (sRIII);
(3) a fusion polypeptide or protein comprising therapeutically active portions of sRII or synthetic analogs thereof;
(4) a fusion polypeptide or protein comprising therapeutically active portions of sRIII or synthetic analogs thereof;
or (5) a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII or synthetic analogs thereof, where the composition includes at least an active portion of sRII and an active portion of sRIII.
2 Assignments
0 Petitions
Accused Products
Abstract
Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGFβ) antagonists are disclosed, where the agents and/or antagonists include a therapeutically effective amount of a combination of therapeutically active portions of sRII and therapeutically active portions of sRIII or a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII. Methods for preventing, treating and/or ameliorating the symptoms of cancer are also disclosed based on administering an effective amount of a composition of this invention.
-
Citations
17 Claims
-
1. A transforming growth factor beta (TGF-beta or TGFβ
- ) antagonist composition comprising a therapeutically effective amount of one or more of;
(1) therapeutically active portions of soluble cell surface type II receptors (sRII);
(2) therapeutically active portions of soluble cell surface type III receptors (sRIII);
(3) a fusion polypeptide or protein comprising therapeutically active portions of sRII or synthetic analogs thereof;
(4) a fusion polypeptide or protein comprising therapeutically active portions of sRIII or synthetic analogs thereof;
or (5) a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII or synthetic analogs thereof, where the composition includes at least an active portion of sRII and an active portion of sRIII. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- ) antagonist composition comprising a therapeutically effective amount of one or more of;
-
13. A transforming growth factor beta (TGF-beta or TGFβ
- ) anti-cancer composition comprising a therapeutically effective amount of one or more of;
(1) therapeutically active portions of soluble cell surface type II receptors (sRII);
(2) therapeutically active portions of soluble cell surface type III receptors (sRIII);
(3) a fusion polypeptide or protein comprising therapeutically active portions of sRII or synthetic analogs thereof;
(4) a fusion polypeptide or protein comprising therapeutically active portions of sRIII or synthetic analogs thereof;
or (5) a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII or synthetic analogs thereof, where the composition includes at least an active portion of sRII and an active portion of sRIII and optionally a non-TGF-beta anti-cancer agent.
- ) anti-cancer composition comprising a therapeutically effective amount of one or more of;
-
14. A method for preventing, treating and/or ameliorating symptoms of cancer comprising the step of administering to an animal including a human a therapeutically effective amount of one or more of:
- (1) therapeutically active portions of soluble cell surface type II receptors (sRII);
(2) therapeutically active portions of soluble cell surface type III receptors (sRIII);
(3) a fusion polypeptide or protein comprising therapeutically active portions of sRII or synthetic analogs thereof;
(4) a fusion polypeptide or protein comprising therapeutically active portions of sRIII or synthetic analogs thereof;
or (5) a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII or synthetic analogs thereof, where the composition includes at least an active portion of sRII and an active portion of sRIII and optionally a non-TGF-beta anti-cancer agent, where the administrating is selected from the group consisting of oral, intravenous, intra-arterial, direct and mixtures or combinations thereof on a single dose basis, periodic dose basis, intermittent dose basis or mixture or combination of these dose basis thereof.
- (1) therapeutically active portions of soluble cell surface type II receptors (sRII);
-
15. A composition for encoding a TBGb antagonist comprising at least two or a plurality of DNA encoding sequences selected from the group consisting of SEQ ID NO. 5, SEQ ID NO. 7, and SEQ ID NO. 9.
-
16. A composition comprising at least two or a plurality of amino acid sequences selected from the group consisting of SEQ ID NO. 6, SEQ ID NO. 8, and SEQ ID NO. 10.
-
17. A method for treating cancer or other human diseases comprising the step of administering an effective amount of a composition comprising at least two or a plurality of DNA encoding sequences selected from the group consisting of SEQ ID NO. 5, SEQ ID NO. 7, and SEQ ID NO. 9 or at least two or a plurality of amino acid sequences selected from the group consisting of SEQ ID NO. 6, SEQ ID NO. 8, and SEQ ID NO. 10 or mixture or combinations thereof.
Specification